三阴性乳腺癌的临床特征及治疗现状  

Clinical feature and current treatment status of triple negative breast cancer

作　　者：高会霞 王彬 周希山 

机构地区：[1]许昌市中心医院放疗科,461000 [2]漯河市五院

出　　处：《中国实用医药》2013年第29期231-233,共3页China Practical Medicine

摘　　要：乳腺癌是女性最常见的恶性肿瘤,病理亚型不同的乳腺癌的生物学行为不同。人表皮生长因子受体-2(HER-2)、雌激素受体(ER)和孕激素受体(PR)均阴性的乳腺癌是三阴性乳腺癌(triplenegativebreastcancer,TNBC),其具有特殊的生物学行为和临床病理学特征。该型乳腺癌组织学分级高,侵袭性强,多为浸润性导管癌,预后较其它亚型的乳腺癌差。虽然三阴性乳腺癌对放化疗敏感,但其复发转移率仍较高,因为缺乏相应的靶向治疗,因此近些年来,三阴性乳腺癌越来越多的得到国际肿瘤学界的关注,本文将近几年来有关三阴乳腺癌的治疗方法和研究进展予以综述。Breast cancer is a kind of normal carcinoma in women, whereas breast cancer with different pathologic subtype present different biological behavior. Triple negative breast cancer is characterized by ER, PR and HER-2, with special biological behavior and pathological feature. This type cancer has high grade and invasiveness, so most of them are invasive duct carcinoma,as a result, they have bad prognosis. Although triple negative breast cancer is sensitive to chemotherapy and radiotherapy, they have high recurrent rate due to lack of targeted therapy. Recent years,therefore, more and more international oncologists focus on triple negative breast cancer. This study summarized the treatment and research progress on triple negative breast cancer within these years.

关 键 词：三阴乳腺癌 放化疗 靶向治疗 

分 类 号：R737.9[医药卫生—肿瘤]